Clinical Trial Update: Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma [EARLY_Phase 1]

View source ↗

Summary

An early-phase clinical trial compares 89Zr-labeled panitumumab with FDG-PET imaging to help identify head and neck squamous cell carcinoma and is currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Fluorodeoxyglucose (FDG) (Fluorodeoxyglucose)
• Panitumumab (Zr-89 labeled) (panitumumab)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Head and Neck Squamous Cell Carcinoma | EARLY_Phase 1 | Status: RECRUITING